fibrinogen concentrate (RiaSTAP)

Indications

• treatment of bleeding in congenital fibrinogen deficiency, including afibrinogenemia & hypofibrinogenemia

Contraindications

• not indicated for dysfibrinogenemia

Dosage

• intravenous infusion
• Dose (mg/kg body weight) =

[Target level (mg/dL) - measured level (mg/dL)]
-----------------------------------------------
1.7 (mg/dL per mg/kg body weight)

• Dose when fibrinogen level is unknown: 70 mg/kg body weight
• monitoring of fibrinogen level is recommended
• target fibrinogen level of 100 mg/dL should be maintained until hemostasis is achieved
• infusion rate should not exceed 5 mL per minute

Single-use vial containing 900-1300 mg of lyophilized powder for reconstitution

Adverse effects

• most serious adverse effects
  • thromboembolism
    • pulmonary embolism
    • myocardial infarction
    • deep vein thrombosis
  • anaphylactic reactions
• most common adverse reactions (>1%)
  • fever
  • headache

Mechanism of action

• human fibrinogen concentrate

More general terms

• fibrinogen; coagulation factor-1
• hematologic agent